PH24090A - 17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as c17020 lyase inhibitors - Google Patents

17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as c17020 lyase inhibitors

Info

Publication number
PH24090A
PH24090A PH36817A PH36817A PH24090A PH 24090 A PH24090 A PH 24090A PH 36817 A PH36817 A PH 36817A PH 36817 A PH36817 A PH 36817A PH 24090 A PH24090 A PH 24090A
Authority
PH
Philippines
Prior art keywords
androst
cyclopropylamino
17beta
3beta
related compounds
Prior art date
Application number
PH36817A
Other languages
English (en)
Inventor
Michael R Angelastro
Thomas R Blohm
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of PH24090A publication Critical patent/PH24090A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
PH36817A 1987-04-22 1988-04-19 17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as c17020 lyase inhibitors PH24090A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4117287A 1987-04-22 1987-04-22

Publications (1)

Publication Number Publication Date
PH24090A true PH24090A (en) 1990-03-05

Family

ID=21915133

Family Applications (1)

Application Number Title Priority Date Filing Date
PH36817A PH24090A (en) 1987-04-22 1988-04-19 17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as c17020 lyase inhibitors

Country Status (19)

Country Link
EP (1) EP0288053B1 (de)
JP (1) JP2711672B2 (de)
KR (1) KR960015037B1 (de)
CN (1) CN88102176A (de)
AT (1) ATE67211T1 (de)
AU (1) AU606677B2 (de)
CA (1) CA1326234C (de)
DE (1) DE3864725D1 (de)
DK (1) DK217588A (de)
ES (1) ES2038712T3 (de)
FI (1) FI88397C (de)
GR (1) GR3002713T3 (de)
HU (1) HU198511B (de)
IL (1) IL86139A (de)
NO (1) NO169346C (de)
NZ (1) NZ224288A (de)
PH (1) PH24090A (de)
PT (1) PT87294B (de)
ZA (1) ZA882717B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891367A (en) * 1987-04-22 1990-01-02 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US4954488A (en) * 1989-06-14 1990-09-04 Merrell Dow Pharmaceuticals Inc. Method of treating hyperaldosteronism using 17β-cyclopropylaminoandrostene derivatives
US4966898A (en) * 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US5209926A (en) * 1990-06-12 1993-05-11 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5256408A (en) * 1990-06-12 1993-10-26 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5252319A (en) * 1990-06-12 1993-10-12 Insite Vision Incorporated Aminosteroids for ophthalmic use
CZ287434B6 (en) * 1992-03-31 2000-11-15 British Tech Group Use of steroids, substituted in position 17, steroids functioning as carcinostatics and pharmaceutical preparation containing thereof
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5486511A (en) * 1993-05-25 1996-01-23 Merrell Dow Pharmaceuticals Inc. 4-amino-17β-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17β-(cyclopropylamino)androst-4-en-3-one and related compounds as C17-20 lyase and 5α-reductase
JP3753971B2 (ja) 2000-11-17 2006-03-08 武田薬品工業株式会社 新規イミダゾール誘導体、その製造法および用途
DE60144246D1 (de) 2000-11-20 2011-04-28 Takeda Pharmaceutical Imidazolderivate, verfahren zu deren herstellung und deren verwendung
AU2002221080A1 (en) 2000-12-08 2002-06-18 Masami Kusaka Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof
UY32730A (es) 2009-06-26 2011-01-31 Novartis Ag Inhibidores de cyp17
KR101926320B1 (ko) 2010-08-04 2018-12-06 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
EP2627648A1 (de) 2010-09-16 2013-08-21 Novartis AG 17a-HYDROXYLASE-C17, 20-LYASE-INHIBITOREN
MX359399B (es) 2011-04-28 2018-09-27 Novartis Ag Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
WO2014158875A1 (en) 2013-03-14 2014-10-02 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
CA2960750A1 (en) 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
WO2018080933A1 (en) 2016-10-24 2018-05-03 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL302932A (de) * 1962-12-31
US4891367A (en) * 1987-04-22 1990-01-02 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors

Also Published As

Publication number Publication date
HUT47307A (en) 1989-02-28
KR880012633A (ko) 1988-11-28
FI881877A0 (fi) 1988-04-21
NO169346C (no) 1992-06-10
FI88397B (fi) 1993-01-29
KR960015037B1 (ko) 1996-10-24
PT87294B (pt) 1992-08-31
ES2038712T3 (es) 1993-08-01
PT87294A (pt) 1988-05-01
DE3864725D1 (de) 1991-10-17
EP0288053A1 (de) 1988-10-26
EP0288053B1 (de) 1991-09-11
ZA882717B (en) 1988-10-17
AU1471988A (en) 1988-10-27
CA1326234C (en) 1994-01-18
JPS63284195A (ja) 1988-11-21
FI88397C (fi) 1993-05-10
NO881746L (no) 1988-10-24
NZ224288A (en) 1989-12-21
IL86139A (en) 1993-02-21
CN88102176A (zh) 1988-11-23
NO169346B (no) 1992-03-02
DK217588A (da) 1988-10-23
HU198511B (en) 1989-10-30
ATE67211T1 (de) 1991-09-15
IL86139A0 (en) 1988-11-15
FI881877A7 (fi) 1988-10-23
JP2711672B2 (ja) 1998-02-10
DK217588D0 (da) 1988-04-21
GR3002713T3 (en) 1993-01-25
AU606677B2 (en) 1991-02-14
NO881746D0 (no) 1988-04-21

Similar Documents

Publication Publication Date Title
PH24090A (en) 17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as c17020 lyase inhibitors
ZA906308B (en) 4-substituted 17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as c17-20lyase inhibitors
GB9514451D0 (en) Sustained-release formulation
IL95359A0 (en) 4-substituted 17beta-(cyclopropylamino-androst-5-en-3beta-ol and related compounds useful as c17-20 lyase inhibitors
IL74552A (en) Process for the microbiological production of l-carnitine and method for deriving micro-organisms suitable for said process
NZ224287A (en) 17b-(cyclopropyloxy)androst-5-en-3b-ol and related compounds useful as c 17-20 lyase inhibitors for treating androgen-dependent disorders
EP0305181A3 (en) Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin
EP0433978A3 (en) New process for the preparation of nojirimycin and related compounds
GR3022779T3 (en) Compounds and methods for treatment of thromboembolic disorders